Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 92 of 92 results for venous thromboembolism

  1. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  2. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)

    Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    21 January 2026
    View recommendations

    Sections for TA1122